INSILENS, A Noetera Company Biotech Intelligence Platform Turn Global Biotech Signals, Into Strategic Intelligence Explore with us Biotech Signals. Structured for Decisions. INSILENS converts global biotech activity into decision-grade intelligence for investors, executives, and business development teams. Deals and Financing ❮ Ultrasound Genetic Medicine Platform Advances Toward Clinic June 10, 2026 GSK Acquires Nuvalent for $10.6B June 9, 2026 Incyte Acquires Vega Therapeutics June 8, 2026 Nurix + Roche; Global BTK Degrader Collaboration June 8, 2026 ❯ Therapeutic Indication ❮ First Potential FDA-Approved Therapy for wAIHA June 11, 2026 Climb Bio Budoprutug Phase 1b, First Anti-CD19 Antibody in ITP June 11, 2026 AbbVie – EHA 2026 Hematology Portfolio Update June 8, 2026 Karyopharm – SENTRY Phase 3 Full Data in Frontline Myelofibrosis June 2, 2026 ❯ Technology Modalities ❮ Parabilis IPO Expansion June 9, 2026 Regeneron – Gene Therapy Approved for Hearing Loss April 24, 2026 Cartherics – CAR-NK Manufacturing Expansion April 15, 2026 Life Biosciences – $80M Gene Therapy Financing April 9, 2026 ❯ View all